LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 72

Search options

  1. Article ; Online: Can Therapeutic Targeting of the Human Microbiome Influence Asthma Management? A Pro/Con Debate.

    Kau, Andrew L / Rosen, Anne L / Rosas-Salazar, Christian

    The journal of allergy and clinical immunology. In practice

    2024  Volume 12, Issue 4, Page(s) 863–869

    Abstract: Asthma is a clinically heterogeneous disease, and despite substantial improvements in therapies, there remains an unmet need for well-tolerated, effective treatments. Observational studies have demonstrated that alterations in the respiratory and gut ... ...

    Abstract Asthma is a clinically heterogeneous disease, and despite substantial improvements in therapies, there remains an unmet need for well-tolerated, effective treatments. Observational studies have demonstrated that alterations in the respiratory and gut microbiome are associated with the development of asthma and its severity. These findings are supported by preclinical models demonstrating that respiratory and gut microbes can alter airway inflammation. Therapeutic approaches to target the human microbiome have been increasingly applied to a wide range of acute and chronic diseases, but there are currently no microbiome-based therapeutics approved for the treatment of asthma. This clinical commentary addresses the future role of microbiome-based therapeutics in asthma management from both a pro and con perspective. We examine (1) the prospects for clinical studies demonstrating a causal relationship between the human microbiome and the severity of asthma; (2) the challenges and potential solutions for designing, testing, and implementing a microbiome-based therapeutic; and (3) the possibility of microbiome-based therapeutics for conditions comorbid to asthma. We conclude by identifying research priorities that will help determine the future of microbiome-based therapeutics for the management of asthma.
    MeSH term(s) Humans ; Microbiota ; Asthma/therapy ; Gastrointestinal Microbiome ; Respiratory System ; Inflammation
    Language English
    Publishing date 2024-01-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2023.12.053
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The INSPIRE study: RSV infection during infancy - Authors' reply.

    Rosas-Salazar, Christian / Gebretsadik, Tebeb / Dupont, William D / Hartert, Tina V

    Lancet (London, England)

    2024  Volume 403, Issue 10428, Page(s) 729–730

    MeSH term(s) Humans ; Respiratory Syncytial Virus Infections/prevention & control ; Risk Factors ; Asthma
    Language English
    Publishing date 2024-02-23
    Publishing country England
    Document type Letter
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(23)02285-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Infant respiratory syncytial virus infection and childhood asthma: A shift in the paradigm?

    Rosas-Salazar, Christian / Hartert, Tina V

    Clinical and translational medicine

    2023  Volume 13, Issue 9, Page(s) e1414

    MeSH term(s) Child ; Humans ; Infant ; Respiratory Syncytial Virus Infections/epidemiology ; Asthma/epidemiology
    Language English
    Publishing date 2023-09-27
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2697013-2
    ISSN 2001-1326 ; 2001-1326
    ISSN (online) 2001-1326
    ISSN 2001-1326
    DOI 10.1002/ctm2.1414
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The biologic asthma response score: A blueprint to address biologic failure in severe asthma?

    Rosas-Salazar, Christian / Bacharier, Leonard B

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

    2023  Volume 132, Issue 1, Page(s) 7–8

    MeSH term(s) Humans ; Asthma/drug therapy ; Anti-Asthmatic Agents/therapeutic use ; Biological Products/therapeutic use
    Chemical Substances Anti-Asthmatic Agents ; Biological Products
    Language English
    Publishing date 2023-12-20
    Publishing country United States
    Document type Editorial
    ZDB-ID 1228189-x
    ISSN 1534-4436 ; 0003-4738 ; 1081-1206
    ISSN (online) 1534-4436
    ISSN 0003-4738 ; 1081-1206
    DOI 10.1016/j.anai.2023.09.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Progress in understanding whether respiratory syncytial virus infection in infancy causes asthma in childhood.

    Rosas-Salazar, Christian / Hasegawa, Kohei / Hartert, Tina V

    The Journal of allergy and clinical immunology

    2023  Volume 152, Issue 4, Page(s) 866–869

    MeSH term(s) Infant ; Humans ; Respiratory Syncytial Virus Infections/complications ; Asthma/complications ; Respiratory Syncytial Virus, Human ; Respiratory Sounds/etiology ; Bronchiolitis ; Bronchiolitis, Viral
    Language English
    Publishing date 2023-08-19
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural
    ZDB-ID 121011-7
    ISSN 1097-6825 ; 1085-8725 ; 0091-6749
    ISSN (online) 1097-6825 ; 1085-8725
    ISSN 0091-6749
    DOI 10.1016/j.jaci.2023.08.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Prevalence, stability, and clinical significance of an isolated low FEV

    Wyatt, MacKenzie L / Sokolow, Andrew G / Brown, Rebekah F / Kaslow, Jacob A / Tolle, James J / Weiner, Daniel J / Rosas-Salazar, Christian

    Pediatric pulmonology

    2024  

    Abstract: Objectives: In adults, an isolated low FEV: Methods: We conducted a retrospective study of spirometries from children ages 6-21 years and categorized tests into spirometry patterns according to published guidelines and recent literature. In a ... ...

    Abstract Objectives: In adults, an isolated low FEV
    Methods: We conducted a retrospective study of spirometries from children ages 6-21 years and categorized tests into spirometry patterns according to published guidelines and recent literature. In a subgroup of tests with an isolated low FEV
    Results: The isolated low FEV
    Conclusions: The isolated low FEV
    Language English
    Publishing date 2024-04-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 632784-9
    ISSN 1099-0496 ; 8755-6863
    ISSN (online) 1099-0496
    ISSN 8755-6863
    DOI 10.1002/ppul.26987
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Defining and Promoting Pediatric Pulmonary Health: Leveraging Patient Reported Outcomes.

    Rosas-Salazar, Christian / Bacharier, Leonard / Buckley, Lisa H / Amaral, Sandra / Sirota, Susan / Moore, Paul E

    Pediatrics

    2023  Volume 152, Issue Suppl 2

    Abstract: Patient-reported outcomes are based on patient (or caregiver) descriptions without direct measurement by a health care provider. To capture patient-reported outcomes, various patient-reported outcome measures (PROMs) have been created. Using PROMs has ... ...

    Abstract Patient-reported outcomes are based on patient (or caregiver) descriptions without direct measurement by a health care provider. To capture patient-reported outcomes, various patient-reported outcome measures (PROMs) have been created. Using PROMs has been linked to improved patient satisfaction, patient-provider communication, and clinical outcomes in many pediatric fields. Despite a long-standing history of utilizing PROMs for the evaluation and management of childhood asthma, pediatric pulmonologists lag behind other pediatric subspecialists in the use of PROMs. During the National Heart, Lung, and Blood Institute's "Defining and Promoting Pediatric Pulmonary Health" workshop, critical knowledge gaps and research opportunities in the use of PROMs for childhood respiratory health were reviewed. In particular, PROMs can be employed as screening tools in the general population for the primary or secondary prevention of pediatric lung diseases. Incorporating these PROMs into the pediatric primary care setting would be especially impactful. In addition, the use of PROMs for the evaluation and management of asthma suggests that they can be applied to other childhood respiratory diseases. Ongoing multicenter studies or national consortia that study pediatric lung diseases could be leveraged to conduct research designed to develop, validate, and assess the utility of PROMs to assess childhood respiratory health. Harnessing the electronic health record will be critical for the successful adoption of PROMs in children with lung diseases. Ultimately, an integrative approach to systematically address numerous barriers at the level of the provider, patient, and health care system will be needed to attain this goal and achieve sustainability.
    MeSH term(s) Humans ; Child ; Asthma/diagnosis ; Asthma/therapy ; Communication ; Electronic Health Records ; Health Personnel ; Patient Reported Outcome Measures
    Language English
    Publishing date 2023-09-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 207677-9
    ISSN 1098-4275 ; 0031-4005
    ISSN (online) 1098-4275
    ISSN 0031-4005
    DOI 10.1542/peds.2023-062292F
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: E-cigarette and vaping product use-associated lung injury in the pediatric population: A critical review of the current literature.

    Kaslow, Jacob A / Rosas-Salazar, Christian / Moore, Paul E

    Pediatric pulmonology

    2021  Volume 56, Issue 7, Page(s) 1857–1867

    Abstract: Use of electronic nicotine delivery systems (ENDS), also known as e-cigarettes, in the adolescent population has significantly increased over the past several years. This rise led to an outbreak of e-cigarette or vaping product use-associated lung injury ...

    Abstract Use of electronic nicotine delivery systems (ENDS), also known as e-cigarettes, in the adolescent population has significantly increased over the past several years. This rise led to an outbreak of e-cigarette or vaping product use-associated lung injury (EVALI) in the summer of 2019. Since that time, numerous case reports and case series on vaping and EVALI have been published but the majority of literature highlights the adult population with few articles focusing on pediatric patients. Given the addictive nature of these products and the lack of full understanding of the human health effects, there is concern that use of ENDS may have lasting impacts on users, especially adolescents and young adults. The goal of this review is to critically assess published data on ENDS use in children, report our institutional experience, discuss the reasons why the use of ENDS have increased among young individuals, outline the current understanding of EVALI as it pertains to the pediatric population, and discuss future opportunities for health policy implementation.
    MeSH term(s) Adolescent ; Child ; Disease Outbreaks ; Dronabinol ; Electronic Nicotine Delivery Systems ; Humans ; Lung Injury/epidemiology ; Vaping/adverse effects ; Young Adult
    Chemical Substances Dronabinol (7J8897W37S)
    Language English
    Publishing date 2021-04-05
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 632784-9
    ISSN 1099-0496 ; 8755-6863
    ISSN (online) 1099-0496
    ISSN 8755-6863
    DOI 10.1002/ppul.25384
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Biologics and severe asthma in children.

    Saxena, Shikha / Rosas-Salazar, Christian / Fitzpatrick, Anne / Bacharier, Leonard B

    Current opinion in allergy and clinical immunology

    2022  Volume 23, Issue 2, Page(s) 111–118

    Abstract: Purpose of review: Severe asthma can carry significant morbidity and mortality for patients, and it places a burden on families and the healthcare system. Biologic agents have revolutionized the care of patients with severe asthma in recent years. ... ...

    Abstract Purpose of review: Severe asthma can carry significant morbidity and mortality for patients, and it places a burden on families and the healthcare system. Biologic agents have revolutionized the care of patients with severe asthma in recent years. Evidence surrounding some of these therapies is limited in the pediatric population, but recent studies show that they significantly improve asthma care when used appropriately. In this review, we discuss the biologic therapies currently approved to treat severe asthma in school-age children and adolescents.
    Recent findings: Randomized controlled trials have been published in support of biologics in children and/or adolescents. These therapies have been shown to reduce the annual rate of severe asthma exacerbations by at least 40-50%, and some up to about 70%. Improvements in asthma control, lung function, oral corticosteroid use, and quality of life have also been demonstrated, although these vary by agent. Furthermore, these therapies have reassuring safety profiles in pediatric patients.
    Summary: With three biologic agents approved for children ages 6-11 years and five approved for adolescents ages >12 years, it can be challenging to select one. The therapy should be chosen after careful consideration of the patient's asthma phenotype and biomarkers. Additional pediatric-specific clinical trials would be helpful in developing evidence-based guidelines on biologic therapies in this population.
    MeSH term(s) Child ; Humans ; Anti-Asthmatic Agents/therapeutic use ; Biological Products/therapeutic use ; Quality of Life ; Asthma/therapy ; Biological Factors/therapeutic use
    Chemical Substances Anti-Asthmatic Agents ; Biological Products ; Biological Factors
    Language English
    Publishing date 2022-11-24
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 2088710-3
    ISSN 1473-6322 ; 1528-4050
    ISSN (online) 1473-6322
    ISSN 1528-4050
    DOI 10.1097/ACI.0000000000000880
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: New Insights Into the Role of Antibiotic Use in Infancy and the Upper Airway Microbiome in Childhood Asthma Development.

    Rosas-Salazar, Christian / Hartert, Tina V

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2020  Volume 72, Issue 9, Page(s) 1555–1556

    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Asthma ; Cohort Studies ; Humans ; Infant ; Microbiota ; Nose
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2020-03-12
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa266
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top